Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Non-LTR Retrotransposons

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...

Antiprotozoal Agents

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Impact of visceral obesity and metabolic syndrome on the postoperative immune, inflammatory, and endocrine response following surgery for esophageal adenocarcinoma.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2017

Same author

Leptin and adiponectin receptor expression in oesophageal cancer.

The British journal of surgery·2014

Same author

Prognostic significance of neuroepithelial transforming gene 1 in adenocarcinoma of the oesophagogastric junction.

The British journal of surgery·2013

Same author

Changes in plasma amino acids during conditioning therapy prior to bone marrow transplantation: Their relevance to antioxidant status.

Amino acids·2013

Same author

Patterns of lymphatic drainage and lymph node involvement in esophageal cancer.

Abdominal imaging·2012

Same author

Role of the insulin-like growth factor 1 axis and visceral adiposity in oesophageal adenocarcinoma.

The British journal of surgery·2012

Search research articles

Related Experiment Video

Updated: Jun 16, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing ¹⁸F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Leptin and gastro-intestinal malignancies.

J M Howard¹, G P Pidgeon, J V Reynolds

¹Department of Clinical Surgery, Institute of Molecular Medicine, Trinity College Dublin, Dublin, Ireland.

Obesity Reviews : an Official Journal of the International Association for the Study of Obesity

|February 13, 2010

Summary

Obesity increases cancer risk, particularly in the gastro-intestinal tract. This review explores how leptin, an adipokine, contributes to obesity-related carcinogenesis and impacts tumor biology.

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Related Experiment Videos

Last Updated: Jun 16, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing ¹⁸F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Area of Science:

Oncology
Endocrinology
Molecular Biology

Background:

Obesity is a known risk factor for several cancers, including gastro-intestinal malignancies.
The precise mechanisms linking obesity to cancer are under investigation, with adipocytokines playing a potential role.
Leptin, a key adipokine, is extensively studied for its involvement in obesity-related carcinogenesis.

Purpose of the Study:

To review the association between leptin and gastro-intestinal tract cancers.
To examine the role of leptin in cell and animal models of these cancers.
To analyze the relationship between leptin levels, tumor characteristics, and patient outcomes.

Main Methods:

Literature review of published data.
Analysis of studies on cell and animal models.
Examination of human tumor data regarding leptin system expression.

Main Results:

Leptin's role in obesity-related carcinogenesis is supported by preclinical and clinical evidence.
Circulating leptin levels correlate with cancer risk and tumor biology.
Leptin system expression in tumors is linked to stage and patient prognosis.

Conclusions:

Leptin is implicated in the development and progression of gastro-intestinal cancers.
Understanding the leptin system offers potential therapeutic targets for obesity-related cancers.
Further research is needed to elucidate leptin's complex role in carcinogenesis.